课题基金 / 基金详情

RECEPTOR SIGNALING, PHYTIC ACID AND PROSTATE CANCER

RECEPTOR SIGNALING, PHYTIC ACID AND PROSTATE CANCER
受体信号传导、植酸和前列腺癌
批准号:
6489322
负责人:
Rajesh Agarwal
金额:
$18.24万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-01-10 至 2003-12-31

项目摘要

项目成果

Rajesh Agarwal的其他基金

相似基金

相关文献

中文摘要
翻译
该基金的总体目标是开展深入研究,以确定和开发基于分子机制的膳食剂植酸对人类前列腺癌(PCA)的干预方法。表皮生长因子受体家族成员(erbB)的异常表达在前列腺上皮内瘤变和侵袭性人前列腺癌中显示出高频率,表明它们在导致该疾病中的作用。除了受体激活外,配体结合还通过内吞作用促进受体聚集到膜上的网格蛋白包覆的凹坑中,然后是受体内化,从而导致受体从细胞表面迅速消失。包覆凹坑的主要结构成分是通过相关蛋白接头(Aps)固定在膜上的网格蛋白晶格。AP2是最普遍存在的特异性与erbB受体相互作用的相关蛋白。除受体外,另一步是通过P13K-AKT-Rab5途径介导的液相内吞作用。基于受体内吞作用与有丝分裂和抗凋亡反应之间的高度关联,我们假设受体介导的和液相内吞作用以及与之相关的有丝分裂和抗凋亡信号的损害是抑制/延缓PCA生长的必要步骤。为了支持这一假设,我们观察到内吞作用在人类PCA细胞中是可操作的,并且膳食剂植酸会损害内吞作用和与之相关的有丝分裂反应。总之,本研究旨在通过损害受体内吞信号导致有丝分裂和抗凋亡反应的抑制,作为植酸干预PCA的一种新颖和创新的策略。利用PCA细胞,我们将评估植酸对1)配体诱导的erbB受体内吞信号传导的抑制作用,并确定AP2和P13K-AKT-Rab5通路在这一过程中的参与;2) mapk介导的生长和P13K-AKT-BAD介导的抗凋亡途径对受体内吞信号通路损伤的响应。接下来,我们将在体外和体内系统中评估植酸对人PCA细胞生长抑制和/或凋亡死亡的生物学意义,并确定上述分子事件的参与。这些研究的结果将为未来的长期研究奠定基础:a)进一步确定受体内吞信号和相关事件在人类PCA中的作用,作为干预的分子靶点;b)在相关实验室研究的研究性临床试验中评估植酸对PCA的作用。
英文摘要
Overall goal of the grant is to conduct in depth studies to identify and develop molecular-mechanism based intervention approach for human prostate cancer (PCA) by a dietary agent phytic acid. Aberrant expression of epidermal growth factor receptor family members (erbB) is shown with high frequency in prostatic intraepithelial neoplasia and invasive human PCA suggesting their role in the causation of this disease. In addition to receptor activation, ligand binding also results in a rapid disappearance of receptor from cell surface via endocytosis by promoting receptor clustering into clathrin- coated pits on membrane followed by receptor internalization. A main structural component of coated pits is clathrin lattice anchored to membrane by associated protein adaptors (Aps). AP2 is the most ubiquitous of associated proteins that specifically interact with erbB receptors. In addition to receptor, the other step is fluid-phase endocytosis mediated via P13K-AKT-Rab5 pathway. Based on high association between receptor endocytosis and mitogenic and anti-apoptotic responses, we hypothesize that impairment of both receptor-mediated and fluid-phase endocytosis, and the mitogenic and anti-apoptotic signaling associated with them is an obligatory step in the inhibition/retardation of PCA growth. In support of this hypothesis, we observed that endocytosis is operational in human PCA cells, and that a dietary agent phytic acid impairs endocytosis and mitogenic responses associated with it. Together, efforts are directed in this grant to impair receptor endocytosis signaling leading to inhibition of both mitogenic and anti-apoptotic responses as a novel and innovative strategy for the intervention of PCA by phytic acid. Using PCA cells, we will assess the inhibitory effect of phytic acid on 1) ligand-induced erbB receptor endocytosis signaling, and define the involvement of AP2 and P13K-AKT-Rab5 pathways in this process; and 2) MAPK-mediated growth and P13K-AKT-BAD- mediated anti-apoptotic pathways in response to impairment of receptor endocytosis signaling. Next, we will assess the biological significance of phytic acid on growth inhibition and/or apoptotic death of human PCA cells using both in vitro and in vivo systems, and define the involvement of molecular events identified above. The outcome of these studies will build a base for future long term studies to a) further define the role of receptor endocytosis signaling and associated events in human PCA as molecular target(s) for intervention, and b) evaluate the effect of phytic acid against PCA in investigative clinical trials with correlative laboratory studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.
  • 批准号:
    10220981
  • 项目类别:
  • 资助金额:
    $72.12万
  • 财政年份:
    2020
  • 负责人:
    Rajesh Agarwal
  • 依托单位:
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.
  • 批准号:
    10472580
  • 项目类别:
  • 资助金额:
    $71.47万
  • 财政年份:
    2020
  • 负责人:
    Rajesh Agarwal
  • 依托单位:
MicroRNAs in Skin Inflammation and Wounding by Mustard Vesicants.
  • 批准号:
    9974481
  • 项目类别:
  • 资助金额:
    $23.33万
  • 财政年份:
    2019
  • 负责人:
    Rajesh Agarwal
  • 依托单位:
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
  • 批准号:
    9326951
  • 项目类别:
  • 资助金额:
    $38.28万
  • 财政年份:
    2014
  • 负责人:
    Rajesh Agarwal
  • 依托单位:
海外基金